News

Houston Oncologist and Professor to be Honored for Lifetime Scientific Achievement

 

Contacts:           
Lisa Rivero                                                                                                         Becky Bunn, MSc
Vice President                                                                                                   Public Relations Manager
lrivero@jpa.com| +1 617-657-1305                                                            Becky.Bunn@IASLC.org | +1 720-254-9509

Houston Oncologist and Professor to be Honored for Lifetime Scientific Achievement
The International Association for the Study of Lung Cancer to Present Mary J. Matthews Pathology/Translation Research Award to Ignacio Wistuba

DENVER, September 11, 2018 - Oncologist and professor Ignacio I. Wistuba, M.D., of The University of Texas MD Anderson Cancer Center, will be recognized by the International Association for the Study of Lung Cancer (IASLC) with a Distinguished Award at the IASLC 19th World Conference on Lung Cancer (WCLC) in Toronto, Canada. Dr. Wistuba will accept the Mary J. Matthews Pathology/Translation Research Award, honoring his lifetime scientific achievements in pathology-translational research of thoracic malignancies.

Dr. Wistuba is chair of the Department of Translational Molecular Pathology, Division of Pathology/Lab Medicine, and is jointly appointed as a professor in the Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center. His research interests include explaining molecular abnormalities involved in the pathogenesis and evolution of lung cancer, as well as identifying new molecular targets and validating biomarkers for targeted therapy.

“Dr. Wistuba has been over many years, and still is, a world leader in pathology and translational science. His work has played a major part in expanding our understanding of premalignant lesions and the molecular mechanisms leading to lung cancer,” said Fred R. Hirsch, M.D., Ph.D., CEO of the IASLC. “He also has contributed significantly to many IASLC activities in a variety of roles, including as current chair of the IASLC Pathology Committee. The IASLC would like to congratulate Dr. Wistuba on this significant accomplishment.”

A molecular pathology and surgical specialist with a robust record of scientific achievement, Dr. Wistuba’s work includes over 400 peer-reviewed articles and multiple book chapters. Additionally, he is a member of The University of Texas Graduate School of Biomedical Sciences, the MD Anderson Cancer Center Vice Provost Advisory Council on Clinical Research (VPAC-CR) and the MD Anderson Cancer Center Sister Institution Network Fund (SINF) Committee, among involvement with other organizations. He is also a pathology liaison with the MD Anderson Cancer Center Institute for Personalized Cancer Therapy (IPCT).

Dr. Wistuba received his medical degree from the Austral University of Chile.

Dr. Wistuba will be honored on September 23, 2018 at the Opening Plenary Session at the IASLC 19th WCLC in Toronto, Canada. The IASLC WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting more than 7,000 researchers, physicians and specialists from more than 100 countries. The IASLC 19th WCLC will take place in Toronto on September 23-26, 2018. The Distinguished Awards are presented each year at the WCLC to the IASLC scientists who have demonstrated excellence in the field of lung cancer research and prevention.

About the WCLC:

The World Conference on Lung Cancer (WCLC) is the world’s largest meeting dedicated solely to lung cancer and other thoracic malignancies, attracting over 7,000 researchers, physicians and specialists from more than 100 countries. The conference will cover a wide range of disciplines and unveil research studies and clinical trial results. For more information, visit www.iaslc.org. Follow the conference on social media with: #WCLC2018.

About the IASLC:

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 7,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information. You can also follow the IASLC on Twitter, Facebook, LinkedIn and Instagram.

# # #

September 11, 2018